MALVERN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen’s Chief Scientific Officer, Head of Research, Development and Medical, will be among the featured speakers at the 4^th Annual Dry AMD Therapeutic Development Summit, which is being held November 14-16, 2023 in Boston, Mass.

Presentation
Session: Gaining a Deeper Understanding of the Underlying Causes of Dry AMD to Inform Therapeutic Drug Development and Target Selection
Topic: Understanding the Complexity of Dry AMD: A Multifactorial Perspective
Date: November 16, 2023
Time: 11 – 11:30 a.m. ET

OCU410, Ocugen’s modifier gene therapy candidate utilizing the nuclear hormone receptor gene RORA, is currently being developed for the treatment of geographic atrophy—an advanced form of dry age-related macular degeneration affecting approximately 1 million people in the United States alone. The Company is enthusiastic about the potential for OCU410 to address unmet medical need in this category and intends to dose patients in the Phase 1/2 trial by the end of 2023.

About Ocugen, Inc. 
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients’ lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release. 

Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com